Last reviewed · How we verify
Fluoropyrimidine- and Platinum-containing Therapy
Fluoropyrimidine- and Platinum-containing Therapy works by interfering with DNA replication and transcription, ultimately leading to cell death.
Fluoropyrimidine- and Platinum-containing Therapy works by interfering with DNA replication and transcription, ultimately leading to cell death. Used for Metastatic colorectal cancer, Metastatic gastric cancer.
At a glance
| Generic name | Fluoropyrimidine- and Platinum-containing Therapy |
|---|---|
| Sponsor | Beijing Biostar Pharmaceuticals Co., Ltd. |
| Drug class | Antineoplastic agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Fluoropyrimidines, such as 5-fluorouracil, inhibit thymidylate synthase, disrupting DNA synthesis. Platinum-containing compounds, like cisplatin, form platinum-DNA adducts, causing DNA damage and triggering apoptosis.
Approved indications
- Metastatic colorectal cancer
- Metastatic gastric cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Diarrhea
- Fatigue
- Anemia
Key clinical trials
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
- A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer (PHASE2)
- Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (PHASE2, PHASE3)
- Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer
- TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma (PHASE1)
- Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer (PHASE3)
- Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: